[1]祝炼 刘春梅 谢莉莉等.不同剂量促红细胞生成素对于早产儿神经发育的作用[J].卒中与神经疾病杂志,2016,23(01):9-11.[doi:10.3969/j.issn.1007-0478.2016.01.003]
　Zhu Lian,Liu Chunmei,Xie Lili,et al.Different doses of erythropoietin protect neural development in premature infant[J].Stroke and Nervous Diseases,2016,23(01):9-11.[doi:10.3969/j.issn.1007-0478.2016.01.003]
点击复制

不同剂量促红细胞生成素对于早产儿神经发育的作用()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第23卷
期数:
2016年01期
页码:
9-11
栏目:
论著
出版日期:
2016-03-01

文章信息/Info

Title:
Different doses of erythropoietin protect neural development in premature infant
作者:
祝炼 刘春梅 谢莉莉等
作者单位: 432000 湖北省孝感市妇幼保健院新生儿科(祝炼); 武汉大学人民医院新生儿科[刘春梅 谢莉莉 李晓鸥 方成志(通信作者)]
Author(s):
Zhu Lian;  Liu Chunmei;  Xie Lili;  et al
Department of Neonatology, Hospital for women and Children's Health Care in Xiaogan, Hubei 432000
关键词:
促红细胞生成素 早产儿 神经发育
Keywords:
Recombinant human erythropoietin Premature infants Nervous system
分类号:
R743
DOI:
10.3969/j.issn.1007-0478.2016.01.003
文献标志码:
A
摘要:
目的 探讨不同剂量促红细胞生成素(rhEPO),对早产儿神经系统发育的影响。方法 入住本院NICU病房的早产儿, 按入院先后次序分为rhEPO组(治疗组)和对照组,其中治疗组120例,对照组30例,其中rhEPO治疗组又随机分为3组,低剂量组(750 U·周·kg-1),中等剂量组(1 500 U·周·kg-1),高剂量组2 000 U·周·kg-1)。比较2组早产儿在纠正胎龄40周时的新生儿神经行为测定(NBNA)评分和6,12月时的Gesell发育量表的评估得分。结果 rhEPO组NBNA评分显著高于对照组,中等剂量和高剂量组分别优于低剂量组(P<0.05),中等剂量和高剂量组无明显差异; 生后6个月时rhEPO组优于对照组大运动和适应能力,12个月时大运动、语言能力及精细动作得分实验组亦高于对照组(P<0.05)。结论 早期使用大剂量 EPO可显著改善早产儿预后,促进其神经系统发育。
Abstract:
ObjectiveThis study of rhEPO treatment in premature, observe whether rhEPO has influence to the development of the nervous system in premature infants, and the effect of different doses have differences.Methods In our NICU ward of premature infants. According to admission order divided into rhEPO treatment group and control group, the treatmentgroup 120 cases, control group 30 cases, Including rhEPO treatment group was randomly divided into three groups, low doses of 750 u·W - 1·kg- 1, medium dose of 1 500 u·W - 1 kg-1, high dose of2 000 u·W - 1 kg-1. Compare two groups of premature infants in the correct determination of neonatalneurobehavioral gestational age at 40 weeks(NBNA)scores and 6 and 12 months of Gesell developmental scale assessment score.Results RhEPO group's NBNA score significantly higher than that of control group, Moderate dose and high dose group's score higher than the low dose group, middle dose and high dose group, no difference; treatment group after 6, 12 months for two groups of children with evaluation of Gesell developmental scale, 6 months big movement and the ability to adapt the experimental group is better than that of control group, 12 months big movement, language and fine motor score of experimental group is higher than that of control group, compared to similar between the two groups have statistical significance.Conclusion The early use of large dose of rhEPO can significantly improve the prognosis of premature infants, promote the development of the nervous system.

参考文献/References:

[1] Zhou TF,Yu JG.Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia[J].J Surg Res,2013,183(1):304-312. -----------------------------------------------
[2] Elmahdy H,El-Mashad AR,El-Bahrawy H,et al.Human recombinant erythropoietin in asphyxia neonatorum: pilot trial[J].Pediatrics,2010,125(5):e1135-e1142.
[3] Bendix I,Schulze C,Haefen Cv,et al.Erythropoietin modulates autophagy signaling in the developing rat brain in an in vivo model of oxygen-toxicity[J].Int J Mol Sci,2012,13(10):12939-12951.
[4] Turner JD,Mammis A,Prestigiacomo CJ.Erythropoietin for the treatment of subarachnoid hemorrhage: a review[J].World Neurosurg,2010,73(5):500-507.
[5] Fan X,Van Bel F,Van Der Kooij MA,et al.Hypothermia and erythropoietin for neuroprotection after neonatal brain damage[J].Pediatr Res,2013,73(1):18-23.
[6] Springborg JB,M?ller C,Gideon P,et al.Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial[J].Acta Neurochir(Wien),2007,149(11):1089-1101; discussion 1101.
[7] Tseng MY,Hutchinson PJ,Richards HK,et al.Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article[J].J Neurosurg,2009,111(1):171-180.
[8] Wu YW,Bauer LA,Ballard RA,et al.Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics[J].Pediatrics,2012,130(4):683-691.
[9] Kumral A,Tüzün F,Oner MG,et al.Erythropoietin in neonatal brain protection: the past, the present and the future[J].Brain Dev,2011,33(8):632-643.
[10] Müller B,Evangelopoulos DS,Bias K,et al.Can S-100B serum protein help to save cranial CT resources in a peripheral trauma centre? A study and consensus paper[J].Emerg Med J,2011,28(11):938-940.
[11] Hempel C,Hyttel P,Staalsø T,et al.Erythropoietin treatment alleviates ultrastructural myelin changes induced by murine cerebral malaria[J].Malar J,2012,11:216.
[12] Wojtczak-Soska K,Lelonek M.S-100B protein: An early prognostic marker after cardiac arrest[J].Cardiol J,2010,17(5):532-536.
[13] Xiong T,Qu Y,Mu D,et al.Erythropoietin for neonatal brain injury: opportunity and challenge[J].Int J Dev Neurosci,2011,29(6):583-591.
[14] 王迎红,朱长连.促红细胞生成素通过早产儿血脑脊液屏障的观察[J].实用儿科临床杂志,2005,20(10):1005-1006.
[15] Fang AY,Gonzalez FF,Sheldon RA,et al.Effects of combination therapy using hypothermia and erythropoietin in a rat model of neonatal hypoxia-ischemia[J].Pediatr Res,2013,73(1):12-17.
[16] Zhu C,Kang W,Xu F,et al.Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy[J].Pediatrics,2009,124(2):e218-e226.
[17] 刘后存,闫平.促红细胞生成素对改善早产儿脑损伤的效果研究[J].中国医药导报,2014,11(12):60-63.

更新日期/Last Update: 1900-01-01